Perforin News and Research

RSS

A striking immune cell pattern emerges around a person’s 100th birthday

Single-cell immune profiling found that CD4 cytotoxic T lymphocytes become more abundant around age 100, showing stepwise differentiation and substantial clonal expansion. Ex vivo experiments also revealed cytokine plasticity within individual clones, supporting the hypothesis that these cells adapt to persistent antigens during healthy aging, although their direct role in longevity remains unproven.

23 Aug 2026

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses.

30 Apr 2026

New insights highlight multifaceted roles of CD4+ T cells in tumor immunity

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell killing.

13 Mar 2026

Vascularized liver tissueoid-on-a-chip recreates tissue regeneration and transplant rejection

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a vascularized liver tissueoid-on-a-chip (LToC) platform that recapitulates key structural, functional, and immunological features of human liver tissue, enabling the study of liver regeneration and immune-mediated allograft rejection in a physiologically relevant human system.

18 Feb 2026

Recent advances in CAR-NK cell therapy could revolutionze cancer treatment

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors.

8 Jan 2026

Engineered CAR-NK cells show enhanced cancer killing and immune evasion

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be programmed to attack cancer cells.

8 Oct 2025

Next generation CAR-T cells push the boundaries of lymphoma treatment

CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic landscape of lymphoma.

23 Jun 2025

Lipid overload in ascites weakens immune response in ovarian cancer

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

13 May 2025

How does SARS-CoV-2 cause lymphopenia when T cells barely express ACE-2 receptors?

Researchers reveal both direct and indirect mechanisms of SARS-CoV-2-induced lymphopenia, highlighting the role of CD147 and alternative viral entry routes into T cells.

8 Jul 2024

Research reveals how Regnase-1 deficiency enhances NK cell tumor killing

Natural killer (NK) cells play a crucial role in the first line of host defense by eliminating bacteria, viruses, and mutated cells that might become cancer cells.

30 May 2024

CRISPR-Cas9 gene-editing tool repairs defective T cells to treat rare hereditary disease

Some hereditary genetic defects cause an exaggerated immune response that can be fatal. Using the CRISPR-Cas9 gene-editing tool, such defects can be corrected, thus normalizing the immune response, as researchers led by Klaus Rajewsky from the Max Delbrück Center now report in "Science Immunology."

2 Feb 2024

Immune dysregulation in long COVID patients uncovered in new study

Sstudy reveals significant immune changes in long COVID patients, including altered T cell responses and systemic inflammation, using advanced 'omics' and serological assays.

14 Jan 2024

Next-generation ovarian cancer therapy: Engineered Vδ2 T cells show promise in preclinical trials

A prospective path for allogeneic cellular immunotherapies.

13 Nov 2023

Multiple sclerosis: Immune cell invasion enabled by blood-brain barrier breakdown

Blood-brain barrier breakdown in multiple sclerosis leads to immune cell infiltration into the central nervous system. Antigen presentation at the barrier promotes CD8+ T cell entry, triggering focal breakdown and hindering their invasion.

4 Jun 2023

Critical COVID-19 infection characterized by a shift from naïve T cell phenotypes to an expansion of cytotoxic CD4+ T lymphocyte subsets

Researchers immunophenotyped T lymphocyte responses among unvaccinated individuals, representative of the entire spectrum of the clinical presentation of COVID-19.

28 Feb 2023

A microbiota-driven mechanism underlies severity of leishmaniasis infection

In a recent study posed to the medRxiv* preprint server, researchers in Brazil and the United States investigated the probable impact of the skin microbiome microbiota on the outcomes of cutaneous leishmaniasis.

8 Feb 2023

Mechanical forces generated by T cells influence the destruction of cancer cells

As a part of our immune defenses, cytotoxic T cells – or killer T cells – seek out and destroy cells that are infected or cancerous. This process is essential for the body's defense against diseases.

15 Sep 2022

Mechanism of action of different COVID-19 vaccines

In a recent study posted to the bioRxiv* preprint server, researchers at the University of Tuebingen and Imperial College London assessed humoral and cellular immune responses elicited by the recombinant adenoviral vector (rAdVV)- and messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines.

14 Sep 2022

Scientists explore associations between SARS-CoV-2 neutralizing antibodies and receptor-binding domain-selective proliferative memory CD4 T cells

Researchers depicted the correlations between receptor-binding domain (RBD)-selective proliferative memory CD4 T cells and neutralizing antibodies in COVID-19 vaccinees and convalescent patients.

27 Jul 2022